Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
Genprex published abstract e15184 at the 2026 ASCO Annual Meeting, presenting positive clinical biomarker data for its lead gene therapy Reqorsa in non-small cell lung cancer (NSCLC). Analysis of 18 patients from ongoing Phase 1/2 trials showed that high Trop-2 H-scores (>100) and low PTEN H-scores (<100) correlated with prolonged progression-free survival in NSCLC patients (p=0.05 and p=0.03, respectively). No such correlation was observed in small cell lung cancer (SCLC) patients, suggesting the biomarker strategy may be specific to NSCLC.
Key figures
- Drug Name
- Reqorsa (quaratusugene ozeplasmid)
- Phase Of Trial
- Phase 1/2
- Patient count
- 18
- Nsclc patients
- 7
- Sclc pten p value
- 0.53
- Nsclc pten p value
- 0.03
- Nsclc trop2 p value
- 0.05
- Pten hscore threshold
- 100
- Trop2 hscore threshold
- 100
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.